Highlights:
- Global discussions spotlight early screening and ROP prevention as critical public health priorities for India
- International collaboration highlights scalable solutions to reduce avoidable childhood blindness
- Innovation-led partnerships key to safeguarding every child’s right to sight
New Delhi, 12th February, 2026: ENTOD Pharmaceuticals, a global ophthalmology-focused pharmaceutical company, reaffirmed its commitment to preventing avoidable childhood blindness in India by participating in global deliberations marking the International Day for a World Without Childhood Blindness. The discussions, led by the Eye Foundation of America (EFA) in collaboration with Rotary International, Lions International, the United Nations, the Commonwealth Secretariat, and civil society institutions, focused on strengthening prevention-led approaches to childhood eye health, including early screening and timely intervention for conditions such as retinopathy of prematurity (ROP).
ENTOD Pharmaceuticals was represented by its Chairman, Mr. Kishore Gurudas Masurkar, and CEO, Mr. Nikkhil K Masurkar, at the commemoration held at the UK House of Lords, one of the world’s most influential legislative chambers. The engagement reflected ENTOD’s focus on aligning global best practices with India’s evolving paediatric eye-care needs.
The initiative was led by the Eye Foundation of America (EFA) in collaboration with Rotary International, Lions International, the United Nations, the Commonwealth Secretariat, and civil society institutions, with a shared objective of strengthening prevention-led approaches to childhood blindness. Discussions placed strong emphasis on ROP prevention, which has emerged as a leading cause of avoidable blindness among premature infants in India.
The high-level forum brought together global health leaders, parliamentarians, policymakers, philanthropists, and vision advocates, including Lord Rami Ranger, Dr. V. K. Raju, Siddharth Chatterjee (United Nations Resident Coordinator), Dr. Varaprasad Reddy, and Dr. Mukesh Batra, underscoring the importance of coordinated, system-level collaboration.
A key global commitment highlighted was a USD 1 million pledge by the Eye Foundation of America to support the launch of India’s National Retinopathy of Prematurity (ROP) Program, in partnership with Rotary and Lions, aimed at strengthening early screening, timely treatment, and access to specialised care for at-risk infants.
Aligned with the UN Sustainable Development Goal 3 (Good Health and Well-Being), the discussions reinforced the importance of innovation-led collaboration in reducing preventable childhood blindness.
For ENTOD Pharmaceuticals, childhood vision care has long been a core focus, driving innovation in paediatric ophthalmology, myopia control, and vision-preserving therapies, and supporting India’s efforts to ensure every child’s right to sight.
About ENTOD Pharmaceuticals
ENTOD Pharmaceuticals is a global research-driven pharma company with over 48 years of expertise in Ophthalmology, ENT, and Dermatology. With 300+ formulations, a 2000+ strong global team, and presence in 67 countries, ENTOD’s products meet the highest international GMP and European-certified quality standards.
Discussion about this post